Compare ABX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABX | SLS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | 326 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.2M | 706.7M |
| IPO Year | N/A | 2007 |
| Metric | ABX | SLS |
|---|---|---|
| Price | $8.35 | $4.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | $10.00 |
| AVG Volume (30 Days) | 666.6K | ★ 6.6M |
| Earning Date | 03-12-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.85 | N/A |
| Revenue Next Year | $6.54 | $67.40 |
| P/E Ratio | $74.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.18 | $0.95 |
| 52 Week High | $10.54 | $6.14 |
| Indicator | ABX | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 43.93 |
| Support Level | $7.18 | $3.35 |
| Resistance Level | $8.78 | $5.01 |
| Average True Range (ATR) | 0.48 | 0.49 |
| MACD | -0.19 | -0.12 |
| Stochastic Oscillator | 1.59 | 0.32 |
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.